Geert Jan Groeneveld
Professor by special appointment of Clinical Neuropharmacology
Geert Jan Groeneveld is professor by special appointment of clinical neuropharmacology at the Leiden University Medical Center. He is a neurologist and clinical pharmacologist and as such sees patients in the pain outpatient clinic of the department of anesthesiology of the LUMC. He is also Chief Medical and Scientific Officer at the Centre for Human Drug Research in Leiden.
The chair of clinical neuropharmacology will be focused on the development and the use of novel pharmacological therapies for the treatment of neurological disorders, including (neuropathic) pain.
In the next 10 years, there will be a strong increase in the range of treatment modalities for neurological diseases in general and specifically for the neurodegenerative disorders. Knowledge of these new drugs is essential. To battle the opioid crisis, new non-opioid analgesics are being developed and can be expected to change the pharmacological treatment of pain in the coming years.
Geert Jan Groeneveld (1971) trained as a Neurologist at the University Medical Center Utrecht, where he also obtained his PhD (2004) on the subject of new pharmacotherapeutic treatment strategies for amyotrophic lateral sclerosis. After his residency neurology (2007) he worked for biotechnology company Genzyme and was involved in studies of recombinant human alpha glucosidase for adult-onset Pompe disease and in gene therapy studies for Parkinson’s Disease. In 2009, he took up the position of Research Director at the Centre for Human Drug Research in Leiden responsible for research in the areas of neurology and pain and obtained a degree in clinical pharmacology in 2014. From 2009 to 2017 he held a position as staff member in the Department of Neurology at the VU University Medical Center in Amsterdam. Since 2017 he has worked as a neurologist in the Pain outpatient clinic of the Department of Anesthesiology at the Leiden University Medical Center, where he sees patients with neurological causes of chronic pain. He has published more than 90 scientific articles in peer-reviewed journals and is actively involved in the training of PhD students. He is a senior editor to the British Journal of Clinical Pharmacology and serves on the editorial boards of Clinical Translational Sciences and Neuropathic Pain, Frontiers in Pain Research.
His inaugural lecture is expected to be held in the spring of 2022.